JPRN-UMIN000003975已完成2 期
Randomized Controlled Trial of Olmesartan Medoxomil Administration in the Prevention of Hepatic Fibrosis in the selected Patients with Cirrhosis - Efficacy of Olmesartan in the Prevention of Hepatic Fibrosis
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) mean arterial pressure <60 mmHg; (2) ARB intolerance; (3) current treatment with ARB, angiotensin-converting enzyme inhibitors, or beta-blockers; (4) hypertrophic cardiomyopathy or renal arterial stenosis; (5) serum creatinine >1.6 mg/dL; (6) hyperkalemia defined as plasma potassium >5.5 meq/L; (7) hepatocellular carcinoma; and (8) portal thrombosis. Current treatment with diuretics was allowed and not changed during the study period.
研究者
相似试验
进行中（未招募）
1 期
Add-on Study of Olmesartan Medoxomil in Patients with Moderate to Severe Hypertension not Achieving Target Blood Pressure on Amlodipine 5 mg AloneEUCTR2005-000450-75-GBSankyo Pharma GmbH632
进行中（未招募）
1 期
Add-on Study of Olmesartan Medoxomil in Patients with Moderate to Severe Hypertension not Achieving Target Blood Pressure on Amlodipine 5 mg AloneEUCTR2005-000450-75-FIDaiichi Sankyo Europe GmbH1,997
进行中（未招募）
不适用
Add-on Study of Olmesartan Medoxomil in Patients with Moderate to Severe Hypertension not Achieving Target Blood Pressure on Amlodipine 5 mg AloneEUCTR2005-000450-75-BESankyo Pharma GmbH632
进行中（未招募）
不适用
Add-on Study of Olmesartan Medoxomil in Patients with Moderate to Severe Hypertension not Achieving Target Blood Pressure on Amlodipine 5 mg AloneEUCTR2005-000450-75-DESankyo Pharma GmbH632
进行中（未招募）
1 期
The efficacy and safety of olmesartan medoxomil/amlodipine fixed combination in patients with mild to moderately elevated blood pressure. An international randomized, double-blind, 10-week clinical InvestigatioEUCTR2014-003470-17-ROKrka, d.d. Novo mesto997